FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior GuidancePreviously Provided FY 2025 Adjusted ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback